Madrigal Pharmaceuticals (NASDAQ: MDGL) — Company Overview, News & Financial Data
Madrigal Pharmaceuticals develops novel therapies for cardiovascular, metabolic, and liver diseases, focusing on NASH.
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease characterized by liver inflammation, fat accumulation, and scarring. The company developed resmetirom (marketed as Rezdiffra), a once-daily oral thyroid hormone receptor-beta selective agonist designed to target the underlying pathways of liver disease. Madrigal secured regulatory approval for Rezdiffra as the first medication for adult patients with noncirrhotic MASH with moderate to advanced liver fibrosis. Headquartered in the United States, Madrigal conducts research, clinical development, regulatory, and commercial activities across North America and key European markets including France, Germany, Italy, Spain, and the United Kingdom.
Snapshot
Operations
Products and/or services of Madrigal Pharmaceuticals
- MASH Therapeutics Commercialization: Development and distribution of once-daily oral thyroid hormone receptor-beta selective agonists designed to treat adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis featuring moderate to advanced liver fibrosis across targeted healthcare markets.
- European Market Expansion: Commercial distribution, market access, and regulatory compliance infrastructure supporting the rollout of liver disease treatments across major European jurisdictions, including France, Germany, Italy, Spain, and the United Kingdom.
- Clinical Trial Pipeline Development: Execution of Phase 3 clinical trial programs and outcome studies evaluating liver fibrosis resolution, long-term clinical outcomes, and safety profiles across diverse patient populations affected by metabolic liver disorders.
- Patient Support Services: Administration of specialized patient assistance initiatives, access navigation programs, financial support tools, and education resources designed to assist healthcare providers and patients in acquiring prescribed oral biopharmaceutical liver treatments.
- Research and Development: Laboratory research, biomarker discovery, and early-stage formulation activities focused on liver biology, thyroid hormone signaling pathways, and novel molecular targets for progressive metabolic and fibrotic diseases.
- Medical Affairs and Scientific Education: Implementation of educational programs, scientific exchange initiatives, and clinical data dissemination targeting hepatologists, endocrinologists, and gastroenterologists to advance clinical understanding of metabolic dysfunction-associated steatohepatitis.
Madrigal Pharmaceuticals executive team
- Mr. William J. SiboldCEO, President & Director
- Dr. Rebecca A. Taub M.D.Founder, Senior Scientific & Medical Advisor and Director
- Ms. Mardi C. DierExecutive VP & CFO
- Ms. Shannon KelleyExecutive VP, Chief Legal Officer & Corporate Secretary
- Ms. Carole HuntsmanExecutive VP & Chief Commercial Officer
- Mr. Mark UnderwoodExecutive Vice President of Business Planning & Operations
- Ms. Rita ThakkarSenior VP & Chief Accounting Officer
- Mr. Ronald FilippoExecutive VP & Chief Information Officer
- Ms. Tina E. VenturaChief Investor Relations Officer
- Mr. Clint WallaceExecutive VP & Chief Human Resources Officer